Moleculin Biotech (MOL) Stock Statistics & Valuation Metrics
Total Valuation
Moleculin Biotech has a market cap or net worth of EUR 7.40M. The enterprise value is EUR 8.88M.
- Market Cap
- EUR 7.40M
- Enterprise Value
- EUR 8.88M
Share Statistics
Moleculin Biotech has 1,050,000 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 1,050,000
- Owned by Insiders
- 6.46%
- Owned by Institutions
- 0.35%
Financial Efficiency
Moleculin Biotech’s return on equity (ROE) is -2.24 and return on invested capital (ROIC) is -162.91%.
- Return on Equity (ROE)
- -2.24
- Return on Assets (ROA)
- -1.52
- Return on Invested Capital (ROIC)
- -162.91%
- Return on Capital Employed (ROCE)
- -1.64
- Revenue Per Employee
- 0
- Profits Per Employee
- -1.97M
- Employee Count
- 17
- Asset Turnover
- 0.00
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Moleculin Biotech is -0.02. Moleculin Biotech’s PEG ratio is -0.00.
- PE Ratio
- -0.02
- PS Ratio
- 0.00
- PB Ratio
- 0.19
- Price to FCF
- -0.32
- Price to Operating Cash Flow
- -0.09
- PEG Ratio
- -0.00
Income Statement
In the last 12 months, Moleculin Biotech had revenue of 0 and earned -33.56M in profits. Earnings per share was -568.40.
- Revenue
- 0
- Gross Profit
- -90.00K
- Operating Income
- -25.10M
- Pretax Income
- -33.56M
- Net Income
- -33.56M
- EBITDA
- -33.47M
- Earnings Per Share (EPS)
- -568.40
Cash Flow
In the last 12 months, operating cash flow was -25.36M and capital expenditures 0, giving a free cash flow of -25.36M billion.
- Operating Cash Flow
- -25.36M
- Free Cash Flow
- -25.36M
- Free Cash Flow per Share
- -89.27
Dividends & Yields
Moleculin Biotech pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -314.90%
- Earnings Yield
- -1351.54%
Stock Price Statistics
- Beta
- 0.59
- 52-Week Price Change
- -99.76%
- 50-Day Moving Average
- 2774.39
- 200-Day Moving Average
- 3112.35
- Relative Strength Index (RSI)
- 0.18
- Average Volume (3m)
- 366
Important Dates
Moleculin Biotech upcoming earnings date is Mar 19, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Aug 14, 2026
- Next Earnings Date
- Mar 19, 2027
- Ex-Dividend Date
- ―
Financial Position
Moleculin Biotech as a current ratio of 1.41, with Debt / Equity ratio of 2.39%
- Current Ratio
- 1.41
- Quick Ratio
- 1.41
- Debt to Market Cap
- 0.03
- Net Debt to EBITDA
- 0.25
- Interest Coverage Ratio
- 0.00
Taxes
In the past 12 months, Moleculin Biotech has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
Moleculin Biotech EV to EBITDA ratio is -0.04, with an EV/FCF ratio of -0.04.
- EV to Sales
- 0.00
- EV to EBITDA
- -0.04
- EV to Free Cash Flow
- -0.04
- EV to Operating Cash Flow
- -0.04
Balance Sheet
Moleculin Biotech has EUR 7.26M in cash and marketable securities with EUR 292.00K in debt, giving a net cash position of EUR 6.97M billion.
- Cash & Marketable Securities
- EUR 7.26M
- Total Debt
- EUR 292.00K
- Net Cash
- EUR 6.97M
- Net Cash Per Share
- EUR 6.64
- Tangible Book Value Per Share
- EUR 1.55
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
- Gross Margin
- 0.00%
- Operating Margin
- 0.00%
- Pretax Margin
- 0.00%
- Net Profit Margin
- 0.00%
- EBITDA Margin
- 0.00%
- EBIT Margin
- 0.00%
Analyst Forecast
The average price target for Moleculin Biotech is EUR 214.28, which is 11.43% higher than the current price. The consensus rating is Strong Buy
- Price Target
- EUR 214.28
- Price Target Upside
- 2719.53% Upside
- Analyst Consensus
- Strong Buy
- Analyst Count
- 3
- Revenue Growth Forecast
- ―
- EPS Growth Forecast
- 86.07%